Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

WPD Pharmaceuticals Inc. (C:WBIO)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
Company Contact
Address: 750 West Pender Street, Suite 401
VANCOUVER BC V6C 2T7
Tel: N/A
Website: https://www.wpdpharmaceuticals.com
IR: See website
Key People
Mariusz Olejniczak
Chief Executive Officer
   
Business Overview
WPD Pharmaceuticals Inc. is a Canada-based clinical-stage pharmaceutical company, with a focus on glioblastoma cancer (GBM) and other brain tumor programs. The Company is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules. It has four novel drug candidates with one in clinical development stage and three in pre-clinical development. It operates its business primarily through WPD Poland, a subsidiary of and the operating branch of the Company. Its portfolio includes WPD101, Berubicin, and WPD103. WPD101 is a family of biopharmaceuticals in preclinical stages of development for targeted treatment of brain tumors with a global license. Berubicin is an anthracycline proven to cross the blood-brain barrier and able to reach brain tumors.
Financial Overview
For the six months ended 30 June 2024, WPD Pharmaceuticals Inc revenues was not reported. Net loss increased 51% to C$177K. Higher net loss reflects Research and development of innovative medicinal products segment loss increase from C$117K to C$263K.
Reporting Currency: Canadian Dollars
Enterprise value: $0.80M as of Jun 30, 2024
Annual revenue (TTM): $0.00M as of Jun 30, 2024
EBITDA (TTM): -$0.35M as of Jun 30, 2024
Net annual income (TTM): -$0.14M as of Jun 30, 2024
Free cash flow (TTM): -$0.19M as of Jun 30, 2024
Net Debt Last Fiscal Year: $0.34M as of Jun 30, 2024
Shares outstanding: 115,987,137 as of Aug 7, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization